Showing results (21-30 of 28) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 28 results.
European Journal of Nuclear Medicine and Molecular Imaging|September 29, 2023
Sentinel lymph node detection in thyroid carcinoma using [<sup>68</sup>Ga]Ga-tilmanocept PET/CT: a proof-of-concept studyLisa H de Vries, Lutske Lodewijk, Tessa Ververs, et al.
European Journal of Nuclear Medicine and Molecular Imaging|April 2, 2025
SUV normalisation and reference tissue selection for [<sup>1</sup>⁸F]mFBG PET-CT in paediatric and adult patientsAtia Samim, Diederik P D Suurd, Rob van Rooij, et al.
Cardiovascular and Interventional Radiology|February 7, 2024
Lung Mean Dose Prediction in Transarterial Radioembolization (TARE): Superiority of [<sup>166</sup>Ho]-Scout Over [<sup>99m</sup>Tc]MAA in a Prospective Cohort StudyMartijn E H M Wagemans, Arthur J A T Braat, Rob van Rooij, et al.
Radiology. Imaging Cancer|November 1, 2024
Safety and Feasibility of Interventional Hybrid Fluoroscopy and Nuclear Imaging in the Work-up Procedure of Hepatic RadioembolizationMartijn M A Dietze, Marjolein B M Meddens, Rob van Rooij, et al.
European Journal of Nuclear Medicine and Molecular Imaging|December 12, 2022
[<sup>18</sup>F]mFBG PET-CT for detection and localisation of neuroblastoma: a prospective pilot studyAtia Samim, Thomas Blom, Alex J Poot, et al.
EJNMMI Physics|March 19, 2025
Towards harmonized holmium-166 SPECT image quality for dosimetry: a multi-center, multi-vendor studyLovisa E L Westlund Gotby, Martina Stella, Camille D E Van Speybroeck, et al.
BMC Gastroenterology|June 16, 2018
Additional hepatic <sup>166</sup>Ho-radioembolization in patients with neuroendocrine tumours treated with <sup>177</sup>Lu-DOTATATE; a single center, interventional, non-randomized, non-comparative, open label, phase II study (HEPAR PLUS trial)Arthur J A T Braat, Dik J Kwekkeboom, Boen L R Kam, et al.
The Lancet. Oncology|March 1, 2020
Additional holmium-166 radioembolisation after lutetium-177-dotatate in patients with neuroendocrine tumour liver metastases (HEPAR PLuS): a single-centre, single-arm, open-label, phase 2 studyArthur J A T Braat, Rutger C G Bruijnen, Rob van Rooij, et al.
Pageof 3